These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 34447272)
1. The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer. Sikic D; Taubert H; Breyer J; Eckstein M; Weyerer V; Keck B; Kubon J; Otto W; Worst TS; Kriegmair MC; Erben P; Hartmann A; Wullich B; Wirtz RM; Wach S Cancer Manag Res; 2021; 13():6567-6578. PubMed ID: 34447272 [TBL] [Abstract][Full Text] [Related]
2. High Androgen Receptor mRNA Expression Is Associated with Improved Outcome in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer. Sikic D; Taubert H; Wirtz RM; Breyer J; Eckstein M; Weyerer V; Kubon J; Erben P; Bolenz C; Burger M; Hartmann A; Wullich B; Wach S; Keck B Life (Basel); 2021 Jun; 11(7):. PubMed ID: 34209360 [TBL] [Abstract][Full Text] [Related]
3. In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival. Breyer J; Wirtz RM; Otto W; Erben P; Kriegmair MC; Stoehr R; Eckstein M; Eidt S; Denzinger S; Burger M; Hartmann A; Virchows Arch; 2017 Mar; 470(3):267-274. PubMed ID: 28074276 [TBL] [Abstract][Full Text] [Related]
4. Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer. Garczyk S; Bischoff F; Schneider U; Golz R; von Rundstedt FC; Knüchel R; Degener S Virchows Arch; 2021 Aug; 479(2):325-335. PubMed ID: 33650041 [TBL] [Abstract][Full Text] [Related]
5. High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma. Breyer J; Wirtz RM; Erben P; Worst TS; Stoehr R; Eckstein M; Bertz S; Sikic D; Denzinger S; Burger M; Hartmann A; Otto W; Clin Genitourin Cancer; 2018 Aug; 16(4):248-256.e2. PubMed ID: 29525349 [TBL] [Abstract][Full Text] [Related]
6. FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer. Breyer J; Wirtz RM; Erben P; Rinaldetti S; Worst TS; Stoehr R; Eckstein M; Sikic D; Denzinger S; Burger M; Hartmann A; Otto W BJU Int; 2019 Jan; 123(1):187-196. PubMed ID: 30120861 [TBL] [Abstract][Full Text] [Related]
7. High Androgen Receptor mRNA Expression Is Independently Associated with Prolonged Cancer-Specific and Recurrence-Free Survival in Stage T1 Bladder Cancer. Sikic D; Breyer J; Hartmann A; Burger M; Erben P; Denzinger S; Eckstein M; Stöhr R; Wach S; Wullich B; Keck B; Wirtz RM; Otto W Transl Oncol; 2017 Jun; 10(3):340-345. PubMed ID: 28342317 [TBL] [Abstract][Full Text] [Related]
8. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma. Rebouissou S; Hérault A; Letouzé E; Neuzillet Y; Laplanche A; Ofualuka K; Maillé P; Leroy K; Riou A; Lepage ML; Vordos D; de la Taille A; Denoux Y; Sibony M; Guyon F; Lebret T; Benhamou S; Allory Y; Radvanyi F J Pathol; 2012 Jul; 227(3):315-24. PubMed ID: 22422578 [TBL] [Abstract][Full Text] [Related]
9. Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of Ecke TH; Kiani A; Schlomm T; Friedersdorff F; Rabien A; Jung K; Kilic E; Boström P; Tervahartiala M; Taimen P; Gleichenhagen J; Johnen G; Brüning T; Koch S; Roggisch J; Wirtz RM Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33050010 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of Fibroblast Growth Factor Receptor 3 (FGFR3) and Tumor Protein P53 (TP53) as Independent Prognostic Biomarkers in High-Grade Non-muscle Invasive Bladder Cancer. Kumar A; Singh VK; Singh V; Singh MK; Shrivastava A; Sahu DK Cureus; 2024 Jul; 16(7):e65816. PubMed ID: 39219882 [TBL] [Abstract][Full Text] [Related]
11. High expression of ERBB2 is an independent risk factor for reduced recurrence-free survival in patients with stage T1 non-muscle-invasive bladder cancer. Sikic D; Eckstein M; Weyerer V; Kubon J; Breyer J; Roghmann F; Kunath F; Keck B; Erben P; Hartmann A; Wirtz RM; Wullich B; Taubert H; Wach S Urol Oncol; 2022 Feb; 40(2):63.e9-63.e18. PubMed ID: 34330652 [TBL] [Abstract][Full Text] [Related]
12. mRNA-Expression of Eckstein M; Wirtz RM; Gross-Weege M; Breyer J; Otto W; Stoehr R; Sikic D; Keck B; Eidt S; Burger M; Bolenz C; Nitschke K; Porubsky S; Hartmann A; Erben P Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30380731 [TBL] [Abstract][Full Text] [Related]
13. [Preoperative Lymphocyte-to-monocyte Ratio Predicts Prognosis in Patients with Stage T1 Non-muscle Invasive Bladder Cancer]. Wang QH; Ji JL; Li H; He PL; Song LX; Zhao Y; Wang HY; Huang T; Sun XX; Cao YW; Dong Z; Shi BB Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2019 Oct; 41(5):622-629. PubMed ID: 31699192 [TBL] [Abstract][Full Text] [Related]
14. FOXA1 Gene Expression for Defining Molecular Subtypes of Muscle-Invasive Bladder Cancer after Radical Cystectomy. Sikic D; Eckstein M; Wirtz RM; Jarczyk J; Worst TS; Porubsky S; Keck B; Kunath F; Weyerer V; Breyer J; Otto W; Rinaldetti S; Bolenz C; Hartmann A; Wullich B; Erben P J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32252315 [TBL] [Abstract][Full Text] [Related]
15. Prognostic value of modified Glasgow Prognostic Score in non-muscle-invasive bladder cancer. Kimura S; D' Andrea D; Soria F; Foerster B; Abufaraj M; Vartolomei MD; Iwata T; Karakiewicz PI; Rink M; Gust KM; Egawa S; Shariat SF Urol Oncol; 2019 Mar; 37(3):179.e19-179.e28. PubMed ID: 30580906 [TBL] [Abstract][Full Text] [Related]
18. Prognostic Factors for Recurrence and Progression in Korean Non-Muscle-Invasive Bladder Cancer Patients: A Retrospective, Multi-Institutional Study. Kim HS; Ku JH; Kim SJ; Hong SJ; Hong SH; Kim HS; Kwon TG; Cho JS; Jeon SS; Joo KJ; Ahn HJ; Park HS; Seong do H; Kwon DD; Kim HJ; Lim JS; Lee HL Yonsei Med J; 2016 Jul; 57(4):855-64. PubMed ID: 27189277 [TBL] [Abstract][Full Text] [Related]
19. Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer. Christensen E; Birkenkamp-Demtröder K; Nordentoft I; Høyer S; van der Keur K; van Kessel K; Zwarthoff E; Agerbæk M; Ørntoft TF; Jensen JB; Dyrskjøt L Eur Urol; 2017 Jun; 71(6):961-969. PubMed ID: 28069289 [TBL] [Abstract][Full Text] [Related]
20. Expression of proteins FGFR3, PI3K, AKT, p21Waf1/Cip1 and cyclins D1 and D3 in patients with T1 bladder tumours: clinical implications and prognostic significance. Blanca Pedregosa AM; Sánchez-González Á; Carrasco Valiente J; Ruiz García JM; Gómez Gómez E; López Beltrán A; Requena Tapia MJ Actas Urol Esp; 2017 Apr; 41(3):172-180. PubMed ID: 27726892 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]